Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Dao Lung Steven Lin has 1 pending office action in the Biotechnology & Pharmaceuticals technology area. This prosecution activity is handled by 1 distinct examiner and is categorized within 1 distinct art unit. The limited scope of this active portfolio suggests a highly specific technical focus for the current patent applications. With only 1 pending office action, the applicant can dedicate significant attention to the specific legal and technical hurdles presented in this single case without the complexity of a larger docket.
The busiest examiner for this profile is PYLA, EVELYN Y, who is responsible for the active workload. Since the busiest examiner pending count is 1, this individual is the sole point of contact for the company's current USPTO interactions. This concentration allows for a focused prosecution strategy, as all efforts are directed toward 1 art unit and 1 examiner rather than being dispersed across multiple pharmaceutical examination groups. Practitioners can tailor their arguments specifically to the past patterns of PYLA, EVELYN Y to optimize the chances of a successful outcome for the 1 pending office action. This level of focus is advantageous for navigating the complex regulatory and technical requirements of the biotechnology sector.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| PYLA, EVELYN Y | 1 | 55.8% | +47.1% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 19411845 | Composition for inhibiting generation of melanin and the use thereof | PYLA, EVELYN Y | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 19411845 | Composition for inhibiting generation of melanin and the use thereof | PYLA, EVELYN Y | — |
| Art Unit | Apps |
|---|---|
| 1633 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 19411845 | Composition for inhibiting generation of melanin and the use thereof | PYLA, EVELYN Y | 1633 | §101§102§103§112DP | Non-Final OA | — | Pending | Dec 08, 2025 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialDao Lung Steven Lin has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Evelyn Y Pyla has the most, with 1 of Dao Lung Steven Lin's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
